van Heerden J, Kruger M. Management of neuroblastoma in limited-resource settings. World J Clin Oncol 2020; 11(8): 629-643 [PMID: 32879849 DOI: 10.5306/wjco.v11.i8.629]
Corresponding Author of This Article
Jaques van Heerden, MD, Doctor, Department of Paediatric Haematology and Oncology, Antwerp University Hospital, No. 10 Wilrijkstreet, Edegem 2650, Belgium. jaques.vanheerden@uza.be
Research Domain of This Article
Oncology
Article-Type of This Article
Systematic Reviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Aug 24, 2020; 11(8): 629-643 Published online Aug 24, 2020. doi: 10.5306/wjco.v11.i8.629
Management of neuroblastoma in limited-resource settings
Jaques van Heerden, Mariana Kruger
Jaques van Heerden, Mariana Kruger, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town 8000, South Africa
Jaques van Heerden, Department of Paediatric Haematology and Oncology, Antwerp University Hospital, Edegem 2650, Belgium
Author contributions: van Heerden J conceptualised and designed the study, sourced and screened articles, collected the data and performed the data analysis and wrote the manuscript; Kruger M conceptualised and designed the study, evaluated the source articles and critically reviewed and edited the manuscript.
Conflict-of-interest statement: All the authors declare that they have no competing interests.
PRISMA 2009 Checklist statement: The guidelines of the PRISMA 2009 Statement have not been adopted, because the review is a descriptive review.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Jaques van Heerden, MD, Doctor, Department of Paediatric Haematology and Oncology, Antwerp University Hospital, No. 10 Wilrijkstreet, Edegem 2650, Belgium. jaques.vanheerden@uza.be
Received: April 28, 2020 Peer-review started: April 28, 2020 First decision: June 20, 2020 Revised: June 23, 2020 Accepted: July 26, 2020 Article in press: July 26, 2020 Published online: August 24, 2020 Processing time: 114 Days and 10.7 Hours
Core Tip
Core tip: Neuroblastoma (NB) is a childhood malignancy of the sympathetic system that accounts for a large percentage of the childhood malignancy mortality. The heterogenous presentation contributes to various treatment challenges especially in low- and middle-income countries (LMICs). NB in LMICs has not been investigated beyond single institutions, but the limited reports differ from those in high-income countries (HICs). The incidence of NB in LMICs has been reported to be lower than HICs, but the disease presents with a higher incidence of high-risk and advanced disease. Furthermore, the limited resources in these countries contribute to the challenges in the management of NB that leads to a high mortality rate. The genetic profile of NB in LMICs is also not known due to limited capacity to perform genetic investigations. This article aims to comprehensively describe NB in LMICs.
